These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 34503676)

  • 1. High-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a): Multi-Ethnic Study of Atherosclerosis.
    Zhang W; Speiser JL; Ye F; Tsai MY; Cainzos-Achirica M; Nasir K; Herrington DM; Shapiro MD
    J Am Coll Cardiol; 2021 Sep; 78(11):1083-1094. PubMed ID: 34503676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between remnant lipoprotein cholesterol, high-sensitivity C-reactive protein, and risk of atherosclerotic cardiovascular disease events in the Multi-Ethnic Study of Atherosclerosis (MESA).
    Chevli PA; Islam T; Pokharel Y; Rodriguez F; Virani SS; Blaha MJ; Bertoni AG; Budoff M; Otvos JD; Shapiro MD
    J Clin Lipidol; 2022; 16(6):870-877. PubMed ID: 36180367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of Lipoprotein-Associated Phospholipase A
    Tibuakuu M; Kianoush S; DeFilippis AP; McEvoy JW; Zhao D; Guallar E; Ballantyne CM; Hoogeveen RC; Blaha MJ; Michos ED
    Am J Cardiol; 2018 May; 121(9):1056-1064. PubMed ID: 29525060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of high sensitivity C-reactive protein in a multi-ethnic population after >10 years of follow-up: The Multi-Ethnic Study of Atherosclerosis (MESA).
    Cainzos-Achirica M; Miedema MD; McEvoy JW; Cushman M; Dardari Z; Greenland P; Nasir K; Budoff MJ; Al-Mallah MH; Yeboah J; Blumenthal RS; Comin-Colet J; Blaha MJ
    Int J Cardiol; 2018 Aug; 264():158-164. PubMed ID: 29776564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein(a), high-sensitivity C-reactive protein, and cardiovascular risk in patients undergoing percutaneous coronary intervention.
    Yuan D; Wang P; Jia S; Zhang C; Zhu P; Jiang L; Liu R; Xu J; Tang X; Song Y; Yao Y; Xu N; Zhang Y; Zhao X; Yang Y; Xu B; Gao L; Gao Z; Gao R; Yuan J
    Atherosclerosis; 2022 Dec; 363():109-116. PubMed ID: 36357218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk.
    Mehta A; Vasquez N; Ayers CR; Patel J; Hooda A; Khera A; Blumenthal RS; Shapiro MD; Rodriguez CJ; Tsai MY; Sperling LS; Virani SS; Blaha MJ; Joshi PH
    J Am Coll Cardiol; 2022 Mar; 79(8):757-768. PubMed ID: 35210030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Sensitivity C-Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study.
    Quispe R; Michos ED; Martin SS; Puri R; Toth PP; Al Suwaidi J; Banach M; Virani SS; Blumenthal RS; Jones SR; Elshazly MB
    J Am Heart Assoc; 2020 Feb; 9(3):e013600. PubMed ID: 32013698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations.
    Small AM; Pournamdari A; Melloni GEM; Scirica BM; Bhatt DL; Raz I; Braunwald E; Giugliano RP; Sabatine MS; Peloso GM; Marston NA; Natarajan P
    JAMA Cardiol; 2024 Apr; 9(4):385-391. PubMed ID: 38353970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent Relationship of Lipoprotein(a) and Carotid Atherosclerosis With Long-Term Risk of Cardiovascular Disease.
    Qi Y; Duan Y; Deng Q; Yang N; Sun J; Li J; Hu P; Liu J; Liu J
    J Am Heart Assoc; 2024 May; 13(9):e033488. PubMed ID: 38639362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein(a) and the pooled cohort equations for ASCVD risk prediction: The Multi-Ethnic Study of Atherosclerosis.
    Bhatia HS; Rikhi R; Allen TS; Yeang C; Guan W; Garg PK; Tsai MY; Criqui MH; Shapiro MD; Tsimikas S
    Atherosclerosis; 2023 Sep; 381():117217. PubMed ID: 37607461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk.
    Mehta A; Virani SS; Ayers CR; Sun W; Hoogeveen RC; Rohatgi A; Berry JD; Joshi PH; Ballantyne CM; Khera A
    J Am Coll Cardiol; 2020 Aug; 76(7):781-793. PubMed ID: 32792075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of First and Total Recurrent Atherosclerotic Cardiovascular Disease Events to Increased Lipoprotein(a) Levels Among Statin Treated Adults With Cardiovascular Disease.
    Wong ND; Zhao Y; Sung J; Browne A
    Am J Cardiol; 2021 Apr; 145():12-17. PubMed ID: 33454339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort.
    Wong ND; Fan W; Hu X; Ballantyne C; Hoodgeveen RC; Tsai MY; Browne A; Budoff MJ
    J Am Coll Cardiol; 2024 Apr; 83(16):1511-1525. PubMed ID: 38631771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular risk: The Multi-Ethnic Study of Atherosclerosis (MESA).
    Rikhi R; Hammoud A; Ashburn N; Snavely AC; Michos ED; Chevli P; Tsai MY; Herrington D; Shapiro MD
    Atherosclerosis; 2022 Dec; 363():102-108. PubMed ID: 36253168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial.
    Puri R; Nissen SE; Arsenault BJ; St John J; Riesmeyer JS; Ruotolo G; McErlean E; Menon V; Cho L; Wolski K; Lincoff AM; Nicholls SJ
    JAMA Cardiol; 2020 Oct; 5(10):1136-1143. PubMed ID: 32639518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Postprocedural High-Sensitivity C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk with ST-Segment Elevation Myocardial Infarction With Percutaneous Coronary Intervention.
    Wang Y; Zhao X; Zhou P; Liu C; Chen R; Sheng Z; Li J; Zhou J; Song L; Zhao H; Yan H
    Am J Cardiol; 2021 Jul; 150():8-14. PubMed ID: 34006374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effect of lipoprotein(a) and high-sensitivity C-reactive protein on the risk of all-cause and cardiovascular death in patients with acute myocardial infarction: a large prospective cohort study.
    Wang Z; Tang J; Shi Q; Fang L; Liu N; Zhang J
    Front Endocrinol (Lausanne); 2024; 15():1392859. PubMed ID: 38812817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
    Yeboah J; Polonsky TS; Young R; McClelland RL; Delaney JC; Dawood F; Blaha MJ; Miedema MD; Sibley CT; Carr JJ; Burke GL; Goff DC; Psaty BM; Greenland P; Herrington DM
    Circulation; 2015 Sep; 132(10):916-22. PubMed ID: 26224808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis.
    Guan W; Cao J; Steffen BT; Post WS; Stein JH; Tattersall MC; Kaufman JD; McConnell JP; Hoefner DM; Warnick R; Tsai MY
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):996-1001. PubMed ID: 25810300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum high-sensitivity C-reactive protein and lipoprotein(a) levels: a comparison between diabetic and non-diabetic patients with coronary artery disease.
    Shahid HS; Kurdi MI; Zohair AA
    Med J Malaysia; 2011 Jun; 66(2):113-6. PubMed ID: 22106689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.